TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: >0.158nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 3.20nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 7.90nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of LRRK2 G2019S mutant in human ANK cells assessed as reduction in Ser935 phosphorylationMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of LRRK2 in human AHE cells assessed as reduction in Ser935 phosphorylationMore data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 63nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 79nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 100nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 126nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant His6-Tev-LRRK2 (1326 to 2527 residues) (unknown origin) using LRRKtide as substrate preincubated for 30 mins followed by su...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 251nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of recombinant full-length LRRK2 (unknown origin) expressed in SH-SY5Y cells assessed as reduction in Ser935 phosphorylation after 60 mins...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B1(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of human OATP1B1More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataIC50: <6.31E+4nMAssay Description:Inhibition of human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 1.58E+5nMAssay Description:Inhibition of human CYP3A4More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 1 group I member 2(Homo sapiens (Human))
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Gsk Pharmaceuticals R&D
Curated by ChEMBL
Affinity DataEC50: <5.01E+4nMAssay Description:Inhibition of human PXRMore data for this Ligand-Target Pair